Evidence map›Paper›PMID 40965672›Full record

ArticleEuropean journal of nutrition2025

Xanthohumol exerts protective function on adriamycin-induced podocyte injury.

Huihui Chen, Hongzhou Lin, Rengcheng Qian, Guoqi Tang, Yinjuan Ding, Yalan Jiang, Xiaoling Guo, Dexuan Wang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huihui Chen *Department of Pediatrics, The Second School of Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Hongzhou Lin *Department of Pediatrics, The Second School of Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Rengcheng Qian *Department of Pediatrics, The Second School of Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Guoqi TangDepartment of PICU, Children's hospital, Zhejiang university school of medicine, National clinical research center for child health, Hangzhou, Zhejiang, China.
Yinjuan DingDepartment of Geriatrics, General Medical Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Yalan JiangThe Center for Geriatric Medicine, Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiaoling GuoDepartment of Pediatrics, The Second School of Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. guoxling@hotmail.com.
Dexuan WangDepartment of Pediatrics, The Second School of Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. wangdexuan@wmu.edu.cn.ORCID http://orcid.org/0000-0002-0261-4749

Funding

the Key Research and Development Program of Zhejiang Province 2023C03018the Public Welfare Science and Technology Plan Project of Wenzhou City Y2020925the Zhejiang Provincial Natural Science Foundation of China LY24H020008
6 · The paper itself

Abstract

purposeNephrotic syndrome (NS) is the main cause of the increasing end-stage renal disease (ESRD) patients worldwide. Podocytes are considered the crucial cells involved in the progression of NS, and their damage can directly lead to proteinuria. The objective of this study was to explore the protective effects of xanthohumol (XN) on podocyte injury.

methodsAdriamycin (ADR)-induced podocyte injury in vivo and in vitro models were established to explore the effects of XN on adriamycin nephropathy (AN) by urine and serum biochemical assay, periodic acid-schiff (PAS) staining, immunohistochemistry, immunofluorescence, western blot, and real-time quantitative PCR (RT-qPCR).

resultsThe results showed that XN could upregulate the expressions of podocyte specific marker Wilms' tumor protein 1 (Wt1), and glomerular filtration related functional proteins such as Nephrin, Synaptopodin, Zonula occludens 1 (ZO-1), and Crumbs2 (Crb2) as well as downregulate the expression of podocyte injury marker Desmin in ADR-treated podocytes to restrain the podocyte actin cytoskeleton disruption.

conclusionOur study showed that XN treatment significantly attenuated ADR-induced podocyte injury, suggesting that XN may be a potential therapy option for patients with NS.

Indexed as

DoxorubicinFlavonoidsPodocytesPropiophenonesProtective AgentsAnimalsHumansMaleMiceNephrotic SyndromeDoxorubicinFlavonoidsPropiophenonesProtective AgentsxanthohumolCrumbs2InjuryNephrotic syndromePodocyteXanthohumol

Identifiers

PMID40965672

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.